eXoZymes (NASDAQ:EXOZ - Get Free Report)'s stock had its "sell (e+)" rating restated by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.
eXoZymes Price Performance
Shares of eXoZymes stock opened at $13.07 on Wednesday. The company has a quick ratio of 6.19, a current ratio of 6.19 and a debt-to-equity ratio of 0.01. eXoZymes has a 12 month low of $8.50 and a 12 month high of $23.99. The business has a fifty day simple moving average of $11.62 and a 200 day simple moving average of $11.60.
eXoZymes (NASDAQ:EXOZ - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter.
eXoZymes Company Profile
(
Get Free Report)
eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider eXoZymes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and eXoZymes wasn't on the list.
While eXoZymes currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
